Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/24927
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJensen, Märit-
dc.contributor.authorSchlemm, Eckhard-
dc.contributor.authorCheng, Bastian-
dc.contributor.authorLettow, Iris-
dc.contributor.authorQuandt, Fanny-
dc.contributor.authorBoutitie, Florent-
dc.contributor.authorEbinger, Martin-
dc.contributor.authorEndres, Matthias-
dc.contributor.authorFiebach, Jochen B-
dc.contributor.authorFiehler, Jens-
dc.contributor.authorGalinovic, Ivana-
dc.contributor.authorThijs, Vincent-
dc.contributor.authorLemmens, Robin-
dc.contributor.authorMuir, Keith W-
dc.contributor.authorNighoghossian, Norbert-
dc.contributor.authorPedraza, Salvador-
dc.contributor.authorSimonsen, Claus Z-
dc.contributor.authorGerloff, Christian-
dc.contributor.authorThomalla, Götz-
dc.date2020-08-28-
dc.date.accessioned2020-10-02T03:26:52Z-
dc.date.available2020-10-02T03:26:52Z-
dc.date.issued2020-08-28-
dc.identifier.citationFrontiers in Neurology 2020; 11: 957en
dc.identifier.issn1664-2295
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/24927-
dc.description.abstractBackground: Hemorrhagic transformation (HT) is an important complication of intravenous thrombolysis with alteplase. HT can show a wide range from petechiae to parenchymal hematoma with mass effect with varying clinical impact. We studied clinical and imaging characteristics of patients with HT and evaluated whether different types of HT are associated with functional outcome. Methods: We performed a post-hoc analysis of WAKE-UP, a multicenter, randomized, placebo-controlled trial of MRI-guided intravenous alteplase in unknown onset stroke. HT was assessed on follow-up MRI or CT and diagnosed as hemorrhagic infarction type 1 and type 2 (HI1 and HI2, combined as HI), and parenchymal hemorrhage type 1 and type 2 (PH1 and PH2, combined as PH). Severity of stroke symptoms was assessed using the National Institutes of Health Stroke Scale (NIHSS) at baseline. Stroke lesion volume was measured on baseline diffusion weighted imaging (DWI). Primary endpoint was a favorable outcome defined as a modified Rankin Scale score 0-1 at 90 days. Results: Of 483 patients included in the analysis, 95 (19.7%) showed HI and 21 (4.4%) had PH. Multiple logistic regression analysis identified treatment with alteplase (OR, 2.08 [95% CI, 1.28-3.40]), baseline NIHSS score (OR, 1.11 [95% CI, 1.05-1.17]), DWI lesion volume (OR, 1.03 [95% CI, 1.01-1.05]), baseline glucose levels (OR, 1.01 [95% CI, 1.00-1.01]) and atrial fibrillation (OR, 3.02 [95% CI, 1.57-5.80]) as predictors of any HT. The same parameters predicted HI. Predictors of PH were baseline NIHSS score (OR, 1.11 [95% CI, 1.01-1.22]) and as a trend treatment with alteplase (OR, 2.40 [95% CI, 0.93-6.96]). PH was associated with lower odds of favorable outcome (OR 0.25, 95% [CI 0.05-0.86]), while HI was not. Conclusion: Our results indicate that HI is associated with stroke severity, cardiovascular risk factors and thrombolysis. PH is a rare complication, more frequent in severe stroke and with thrombolysis. In contrast to HI, PH is associated with worse functional outcome. The impact of HT after MRI-guided intravenous alteplase for unknown onset stroke on clinical outcome is similar as in the trials of stroke thrombolysis within a known early time-window.en
dc.language.isoeng
dc.subjectWAKE-UPen
dc.subjecthemorrhagic transformationen
dc.subjectintracerebral hemorrhageen
dc.subjectischemic Strokeen
dc.subjectthrombolysisen
dc.titleClinical Characteristics and Outcome of Patients With Hemorrhagic Transformation After Intravenous Thrombolysis in the WAKE-UP Trial.en
dc.typeJournal Articleen
dc.identifier.journaltitleFrontiers in Neurologyen
dc.identifier.affiliationKlinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf, Hamburg, Germanyen
dc.identifier.affiliationNeurologyen
dc.identifier.affiliationGerman Center for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germanyen
dc.identifier.affiliationGerman Center for Neurodegenerative Disease (DZNE), Partner Site Berlin, Berlin, Germanyen
dc.identifier.affiliationKlinik und Hochschulambulanz für Neurologie, Charité-Universitätsmedizin Berlin, Berlin, Germanyen
dc.identifier.affiliationNeurologie, Medical Park Berlin Humboldtmühle, Berlin, Germanyen
dc.identifier.affiliationThe Florey Institute of Neuroscience and Mental Healthen
dc.identifier.affiliationCentrum für Schlaganfallforschung Berlin (CSB), Charité-Universitätsmedizin Berlin, Berlin, Germanyen
dc.identifier.affiliationCNRS, UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique-Santé, Villeurbanne, Franceen
dc.identifier.affiliationUniversité Lyon 1, Villeurbanne, Franceen
dc.identifier.affiliationHospices Civils de Lyon, Service de Biostatistique, Lyon, Franceen
dc.identifier.affiliationVIB, Laboratory of Neurobiology, Center for Brain & Disease Research, Leuven, Belgiumen
dc.identifier.affiliationDepartment of Neurosciences, Experimental Neurology, KU Leuven-University of Leuven, Leuven, Belgiumen
dc.identifier.affiliationDepartment of Neurology, University Hospitals Leuven, Leuven, Belgiumen
dc.identifier.affiliationCentrum für Schlaganfallforschung Berlin (CSB), Charité-Universitätsmedizin Berlin, Berlin, Germanyen
dc.identifier.affiliationDepartment of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germanyen
dc.identifier.affiliationCentrum für Schlaganfallforschung Berlin (CSB), Charité-Universitätsmedizin Berlin, Berlin, Germanyen
dc.identifier.affiliationInstitute of Neuroscience and Psychology, University of Glasgow, Glasgow, United Kingdomen
dc.identifier.affiliationDepartment of Stroke Medicine, Université Claude Bernard Lyon 1, Hospices Civils de Lyon, Lyon, Franceen
dc.identifier.affiliationDepartment of Radiology, Institut de Diagnostic per la Image (IDI), Hospital Dr. Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI), Girona, Spainen
dc.identifier.affiliationDepartment of Neurology, Aarhus University Hospital, Aarhus, Denmarken
dc.identifier.affiliationKlinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf, Hamburg, Germanyen
dc.identifier.doi10.3389/fneur.2020.00957en
dc.type.contentTexten
dc.identifier.pubmedid32982951
local.name.researcherThijs, Vincent N
item.grantfulltextnone-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
crisitem.author.deptNeurology-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

34
checked on Nov 18, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.